Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · U.S. Code · Title 21 - FOOD AND DRUGS · CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT · SUBCHAPTER IX— TOBACCO PRODUCTS · § 387r

§ 387r. Drug products used to treat tobacco dependence

436 words·~2 min read·/usc/title-21/section-387r

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(a)In general The Secretary shall—
(1)at the request of the applicant, consider designating products for smoking cessation, including nicotine replacement products as fast track research and approval products within the meaning of section 356 of this title;
(2)consider approving the extended use of nicotine replacement products (such as nicotine patches, nicotine gum, and nicotine lozenges) for the treatment of tobacco dependence; and
(3)review and consider the evidence for additional indications for nicotine replacement products, such as for craving relief or relapse prevention.
(b)Report on innovative products
(1)In general Not later than 3 years after June 22, 2009, the Secretary, after consultation with recognized scientific, medical, and public health experts (including both Federal agencies and nongovernmental entities, the Institute of Medicine of the National Academy of Sciences, and the Society for Research on Nicotine and Tobacco), shall submit to the Congress a report that examines how best to regulate, promote, and encourage the development of innovative products and treatments (including nicotine-based and non-nicotine-based products and treatments) to better achieve, in a manner that best protects and promotes the public health—
(A)total abstinence from tobacco use;
(B)reductions in consumption of tobacco; and
(C)reductions in the harm associated with continued tobacco use.
(2)Recommendations The report under paragraph
(1)shall include the recommendations of the Secretary on how the Food and Drug Administration should coordinate and facilitate the exchange of information on such innovative products and treatments among relevant offices and centers within the Administration and within the National Institutes of Health, the Centers for Disease Control and Prevention, and other relevant agencies.
(June 25, 1938, ch. 675, § 918, as added Pub. L. 111–31, div. A, title I, § 101(b)(3), June 22, 2009, 123 Stat. 1825.)
Connections3 cite this · traces to 3
5 references not yet in our index
  • June 25, 1938, ch. 675, § 918
  • Pub. L. 111–31, div. A, title I, § 101(b)(3)
  • 123 Stat. 1825
  • Pub. L. 111–31
  • section 6 of Pub. L. 111–31
Citation graph
cites case law
§ 387r
Drug products used to treat tobacco dependence
Fed. Reg.×2
Stat.×1
ActJune 25, 1938, ch. 675, § 918
Pub. L.Pub. L. 111–31, div. A, title I, § 101(b)(3)
Stat.123 Stat. 1825
Pub. L.Pub. L. 111–31
Pub. L.section 6 of Pub. L. 111–31
Cites 8Cited by 3 across 2 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.